Results

1–10 of 297 results for trial

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2024
BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)
Michael A. Singer, MD
Annual Meeting Talks
2024
Interim Safety and Efficacy Results From the Phase 1 HELIOS Trial of Sustained-Release Axitinib Implant (OTX-TKI) for NPDR
Dilsher S. Dhoot, MD
Annual Meeting Talks
2024
Assessment on Pre-to-Post Switching Efficacy and Safety of SB15 (Proposed Aflibercept Biosimilar): Post Hoc Analysis of a Phase 3 Clinical Trial
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2024
Silicone Oil Droplets in the Vitreous After Intravitreal Injection With a Silicone Oil-Free and a Siliconized Insulin Syringe: A Randomized Clinical Trial
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2024
IL-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Phase 3 MEERKAT and SANDCAT Trials
Anat Loewenstein, MD
Annual Meeting Talks
2024
Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase 2 Skyline Trial
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2024
Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Annual Meeting Talks
2024
Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Annual Meeting Talks
2024